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Abstract
Background: Isolated renal hypophosphatemia may be inherited or acquired. An increasing number of patients
with unexplained renal hypophosphatemia is being referred to our clinics, but the optimal diagnostic work-up is
not known. Therefore, the aim of this study was to assess the diagnostic yield in these patients.
Methods: We retrospectively evaluated all patients who were referred because of unexplained isolated renal
hypophosphatemia to two academic tertiary referral centers in The Netherlands in the period of 2013–2017.
Results: We evaluated 17 patients. In five female patients renal hypophosphatemia could be attributed to the use
of oral contraceptives. The other 12 patients had a median age of 48 years (10 males). There were no other signs of
tubulopathy and none of the patients used drugs known to be associated with hypophosphatemia. FGF23 levels
were above normal (> 125 RU/ml) in 2/12 patients. Genetic testing, performed in all patients, did not identify a
mutation in genes known to be associated with renal phosphate wasting. A scan with a radiolabeled somatostatin
analogue was performed in 8 patients. In one patient, with an FGF23 level of 110 RU/ml, an increased uptake of the
somatostatin analog was observed due to tumor induced osteomalacia (TIO).
Conclusions: Oral contraceptive use is an important but under-recognized cause of renal hypophosphatemia. The
cause of isolated renal hypophosphatemia remained unexplained in the majority of other patients despite extensive
and expensive additional investigations. The pre-test probability for tumor-induced osteomalacia or inherited renal
hypophosphatemia in a patient with aspecific complaints and a normal FGF23 level is low. Further research is
needed to investigate which patients should be screened for TIO. At present we suggest to perform somatostatin
scans only in patients with severe complaints, elevated FGF23 levels, or progressive disease.
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Background
Phosphate is freely filtered by the glomerulus and 80–90% is
reabsorbed at the brush border membrane of the proximal
tubule, through apical sodium-dependent phosphate trans-
porters (primarily NaPi2a and NaPi2c). The principal regula-
tors of this transcellular phosphate reabsorption are dietary
phosphate, parathyroid hormone (PTH), 1,25 dihydroxy
vitamin D3 (1,25OHD3) and fibroblast growth factor 23
(FGF23). A defect in one of these transporters or perturb-
ation in one of the regulating factors can result in increased
renal phosphate loss. Various inherited phosphate wasting
disorders have been identified, including X-linked autosomal
hypophosphatemia (XLH; due to a mutation in PHEX),
autosomal dominant hypophosphatemic rickets (ADHR;
due to impaired cleavage of FGF23 caused by a mutation in
FGF23), autosomal recessive hypophosphatemic rickets
(ARHR; due to a mutation in DMP1) and Fanconi renotub-
ular syndrome-2 (dysfunction of NaPi2a due to homozygous
mutations in SLC34A1) [1]. Some of these inherited disor-
ders, such as ADHR, can become apparent after childhood,
which can make the differentiation with acquired disorders
difficult. The most common causes of acquired isolated
renal hypophosphatemia are drugs (for example acetazol-
amide, bisphosphonates, diuretics, glucocorticosteroids,
imatinib, acyclovir, aminoglycosides, tenofovir and valproic
acid), hyperparathyroidism and tumor induced osteomalacia
(TIO) [2]. TIO is a rare disorder in which there is renal
phosphate wasting due to tumors that secrete phosphaturic
factors (most commonly FGF23) [3–5].
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The cause of hypophosphatemia is often identified
during the initial diagnostic evaluation of patients pre-
senting with (renal) hypophosphatemia. Yet, an increas-
ing number of patients is being referred to our clinics
because of unexplained chronic renal hypophosphate-
mia. The optimal diagnostic work-up of these patients is
not known. We report the diagnostic yield of extensive
evaluation in these patients.
Methods
We retrospectively evaluated all patients who were referred
because of unexplained chronic renal hypophosphatemia,-
which was confirmed on several occasions, to two university
hospitals in The Netherlands in the period of 2013–2017.
In these patients, well-known causes of acquired renal
hypophosphatemia had been previously excluded. Renal
hypophosphatemia was defined as a serum phosphate below
0.70 mmol/l and an inappropriately high renal phosphate
excretion. Fractional excretion of phosphate was calculated
as (urine phosphate * serum creatinine)/(serum phosphate *
urine creatinine). TmP/GFR was calculated by the method
of Bijvoet [6]. All measurements were performed during
low serum phosphate levels. The reference value for serum
phosphate in our centers is 0.80–1.40 mmol/l (variation co-
efficient of 3.7%). In most patients a fasting serum phos-
phate was measured at 8.00 am because it is known that
serum phosphate shows a circadian rhythm with the lowest
value between 8.00–11.00 am [7, 8]. To exclude that the
hypohosphatemia was due to this circadian rhythm, we de-
termined serum phosphate in 100 fasting anonymous sam-
ples of patients visiting the outpatient clinic with an eGFR
> 60 ml/min/1.73 m2, withdrawn between 8.00–10.00 am.
The mean serum phosphate level was 1.06 mmol/l (SD
0.17, range 0.67–1.42 mmol/l), indicating that the hypopho-
sphatemia in our patients was not the result of the early
morning blood sampling.
General (proximal) tubular dysfunction was assessed by
measuring glucose, pH, urate and α1-microgobulin in
urine. Glucose, calcium, potassium, creatinine (enzymatic
method) and phosphate were measured on a Cobas c6000
(Roche, Switzerland) or c18000 (Abbott, USA) analyzer.
The α1-microgobulin concentration in urine was mea-
sured on a BNII nephelometer (Siemens, Germany) and
urinary pH was measured with a PHM220 potentiometer
(Hach Lange Nederland, the Netherlands). Genetic testing
for mutations in genes that are known to be associated with
renal phosphate wasting (DMP1, FGF23, FGFR1, GALNT3,
PHEX, SLC34A1, SLC34A3, SLC9A3R1) was done by
Sanger sequencing and MPLA on genomic DNA derived
from peripheral blood cells. Vitamin D was measured by
LC-MSMS. Intact PTH (second generation) was measured
by an ECLIA on a modular E170 analyzer (Roche,
Switzerland). FGF23 was measured by an ELISA of Immu-
topics measuring both intact FGF23 and C-terminal
fragments, San Clemente, CA, USA. Somatostatin scans
were performed per protocol in all patients with an elevated
FGF23 level. In addition, somatostatin scans were per-
formed in some patients with a normal FGF23 level at the
discretion of the treating physician. These scans use som-
atostatin analogs (pentetreotide, TOC, TATE or NOC),
which are labelled with tracer molecules (111Indium, 68Gal-
lium or 99 Technetium) and sometimes a chelator molecule
(DOTA). The somatostatin scans that were used in our
clinics are the 68Ga-DOTA-TOC PET/CT scan and the
111Indium-pentetreotide SPECT/CT scan.
Results
Seventeen patients with unexplained chronic renal hypo-
phosphatemia were evaluated. The median age was
42 years old, 10 patients were male and there were no
other signs of tubulopathy in any of these patients.
Five female patients used oral contraceptives, containing
estrogens, at the time of referral. Their demographical and
clinical characteristics are shown in Table 1. After discon-
tinuing the oral contraceptives, renal hypophosphatemia re-
solved in all patients with normalisation of serum
phosphate levels (Fig. 1). TmP/GFR was measured in three
patients before and after stopping the oral contraceptives
and increased from 0.58 mmol/l (range 0.30–0.62) to
0.92 mmol/l (range 0.78–0.95). A re-challenge with the oral
contraceptive was performed in one patient after which
renal hypophosphatemia re-emerged. Characteristics of the
other 12 patients are shown in Table 1. PTH was above nor-
mal (8.7 pmol/l) in only one patient. This patient did not
have vitamin D deficiency and calcium excretion was nor-
mal (5 mmol/day). One patient had a 25-hydroxyvitamin D
(25OHD) level below 50 nmol/l together with a slightly ele-
vated 1,25OHD3 level of 206 pmol/l. 1,25OHD3 was above
normal in another four patients and FGF23 was above 125
RU/ml in two patients.
Genetic testing, which was performed in all remaining
patients, did not show any mutation in genes known to
be associated with renal phosphate wasting.
The two patients with an FGF23 level above 125 RU/ml
both underwent an 111Indium-pentetreotide SPECT/CT.
These scans did not show increased somatostatin uptake
that would have been suggestive of TIO. Three additional
patients, with normal FGF23 levels, underwent an
111Indium-pentetreotide SPECT/CT and three additional
patients a 68Ga-DOTA-TOC PET/CT scan, at the discre-
tion of the treating physician. One of these six scans, a
68Ga-DOTA-TOC PET/CT scan, showed increased uptake
in the right lateral femur suggestive of TIO. This patient
had a normal serum FGF23 level of 110 RU/ml but pro-
gressive hypophosphatemia which required increasing
doses of phosphate replacement. In this patient the tumor
in the femur was resected (histology showed an enchon-
droma) after which renal hypophosphatemia resolved.
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Discussion
Our study shows that in female patients presenting
with previously unexplained renal hypophosphatemia,
estrogen-induced hypophosphatemia due to oral
contraceptive use appears to be frequent. In 5 out of 7 fe-
male patients the hypophosphatemia could be attributed
to the use of oral contraceptives. This is a relatively un-
known and often overlooked cause of renal phosphate
loss. No previous study reported hypophosphatemia as the
result of oral contraceptive use, but a decrease in serum
phosphate has been described in response to estrogen re-
placement therapy in postmenopausal women [9–12].
This decrease in serum phosphate was accompanied by a
decrease in TmP/GFR, confirming renal phosphate wast-
ing [11, 12]. The estrogen content of the replacement
therapy that was used in these postmenopausal women
was higher than the estrogen content in oral contracep-
tives in our patients (50 μg to 62.5 μg compared to 30 μg).
Treatment with even higher doses of diethylstilbestrol
diphoshate in male patients with metastatic prostate can-
cer also resulted in lowering of serum phosphate in 16 out
of 18 patients [13]. Urinary parameters were measured in
three of these patients, and were compatible with in-
creased renal phosphate loss. Thus, the pathophysiological
mechanism of the renal phosphate loss with oral contra-
ceptive use is most likely related to the estrogen content.
Indeed, estrogen treatment in ovariectomized rats and
mice results in renal hypophosphatemia. In these animals
both NaPi2a en NaPi2c in the proximal tubule were
shown to be down regulated [14–16].
In 11/12 of the remaining patients the underlying
cause of renal hypophosphatemia remained unknown,
despite extensive diagnostic evaluation. Although genetic
testing did not reveal a mutation, this does not rule out
genetic causes as we might still have missed mutations
of which the significance is not yet understood.
Table 1 Patient characteristics
Oral contraceptive induced
hypophosphataemia (N = 5)
Unexplained renal
hypophosphataemia (N = 12)
Reference value
Age (years) 34 (28–53) 48 (24–64
Gender (M/F) 0/5 10/2
Serum phosphate (mmol/l) 0.62 (0.33–0.65) 0.59 (0.36–0.77) 0.80–1.40
TmP/GFR (mmol/l) 0.58 (0.30–0.68) 0.50 (0.38–0.55) 0.80–1.40
FePi (%) 11 (4–13) 18 (5–35) < 5
Serum creatinine (μmol/l) 74 (62–77) 87 (53–142) 60–110
eGFR (ml/min/1.73m2)a 95 (80–118) 95 (45–122) > 90
Serum calcium (mmol/l) 2.27 (2.20–2.33) 2.39 (2.27–2.59) 2.20–2.65
serum potassium (mmol/l) 3.9 (3.7–4.4) 3.9 (3.5–4.5) 3.5–4.7
Serum magnesium (mmol/l) 0.80 (0.79–0.91) 0.82 (0.78–0.95) 0.70–1.10
PTH (pmol/l) 5.3 (4.7–6.6) 5.2 (3.2–8.7) 1.0–6.5
25OHD(nmol/l) 106 (57–148) 72 (40–135) > 50
1,25OHD3 (pmol/l) 169 (129–246) 140 (78–322) 50–150
cFGF23 (RU/ml) 66 (48–124) 89 (53–202) < 125
24 h urinary calcium excretion (mmol) 3 (2.2–4.8) 5.5 (0.6–11.0) < 5.0
Values are given as median (range)
FePi = fractional excretion of phosphate
aeGFR was calculated by CKD-EPI formula
Fig. 1 Course of serum phosphate levels before and after stopping
oral contraceptives in 5 women
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One patient was diagnosed with TIO. This diagnosis
was made after this patient underwent a somatostatin
scan, despite a normal serum level of FGF23, because he
suffered from progressive hypophosphatemia.
Although most reported patients withTIO have clearly el-
evated serum FGF23 levels, fourteen TIO patients with nor-
mal FGF23 levels have been described in literature
previously [17–25]. In these patients another phosphaturic
hormone could be involved or FGF23 levels could have
been misinterpreted due to the use of incorrect reference
values and/or FGF23 assays.
Intact FGF23 (iFGF23) is degraded by proteolytic
cleavage into inactive N- and C-terminal fragments [26,
25]. Since iFGF23 is rapidly degraded ex-vivo, special
sampling procedures are required with the use of prote-
ase inhibitors [27]. In routine clinical practice in our
country, a commercially available assay is used that mea-
sures both intact FGF23 and the C-terminal fragments.
Therefore, we cannot exclude that some patients might
have had increased iFGF23 values in the presence of
normal cFGF23 values. Furthermore, reference values
are based on studies in healthy volunteers. Ideally,
FGF23 values in our patients with hypophosphatemia
should be compared to FGF23 values in persons with
FGF23-independent hypophosphatemia. Although iFGF23
is decreased in such patients [17, 28, 29], validated refer-
ence values of FGF23 adjusted for severe phosphate deficit
do not exist.
We could have missed TIO’s because a somatostatin scan
was not performed in all patients and because of low sensi-
tivity of the scanning technique. Scans with radiolabeled
somatostatin analogs are being used for the diagnosis of
TIO as these tumors are of mesenchymal origin and fre-
quently express somatostatin receptors (mostly SSTR 2 and
5) [22, 30–32]. The scans differ in affinity for SSTR’s and
spatial resolution. PET-based imaging has better spatial
resolution and signal-to-noise ratios as compared to
SPECT-based imaging. The somatostatin analogues also
differ in their affinity for various somatostatin receptor sub-
types. DOTA-conjugated peptides have 4–8 higher affinity
to SSTR2 than 111Indium-pentetreotide [22, 33, 31].
DOTANOC has affinity for a wide range of receptors like
SSTR1, 2, 3 and 5, while DOTATATE and DOTATOC bind
more avidly to SSTR2 [34, 35]. The exact percentage of
SSTR positive tumours in TIO is not known, neither is the
exact sensitivity of the different scanning techniques for
diagnosing TIO.
Since tumors causing TIO typically are slow growing
neoplasms that are benign in behaviour, a defensive
diagnostic approach seems justified. We therefore do
not advocate to immediately perform a somatostatin
scan in all patients with unexplained chronic renal hypo-
phosphatemia. We suggest to perform somatostatin
scans only in patients with severe complaints including
bone pain and fractures, elevated FGF23 levels, progres-
sive disease and/or increasing FGF23 levels.
Another striking finding is the male predominance of the
group of patients with an unexplained renal hypophospha-
temia. This raises the question whether endogenous testos-
terone, in analogy to exogenous estrogen, plays a role in the
phosphate loss. Supporting this theory is the negative cor-
relation between serum testosterone and serum phosphate
in men in the general population [36]. Data about the effect
of testosterone therapy on serum phosphate is conflicting
[37, 38] but testosterone depletion (states) seems to induce
an increase in serum phosphate due to increased tubular
phosphate re-absorption [39–41]. We did not test whether
serum testosterone levels were elevated in our patients.
A main limitation of our paper is the retrospective study
design, in which the analyses were performed to the dis-
cretion of the treating physician. Another limitation is the
lack of other proximal tubular function markers such as
aminoaciduria, which could be helpful to differentiate iso-
lated renal hypophosphatemia from a more general prox-
imal tubular defect as seen in Fanconi syndrome.
Conclusions
In conclusion, oral contraceptive use is an important but
under-recognized cause of isolated chronic renal hypopho-
sphatemia. The cause of chronic renal hypophosphatemia
remained unexplained in the majority of other patients des-
pite extensive and expensive additional investigations. The
pre-test probability for TIO or inherited renal hypophospha-
temia in a patient with aspecific complaints and a normal
FGF23 level is low. Further research is needed to investigate
which patients should be screened for TIO with measure-
ments of both cFGF23 and iFGF23 and DOTA-conjugated
SPECT scans. At present we suggest to perform somato-
statin scans only in patients with severe complaints includ-
ing bone pain and fractures, elevated FGF23 levels,
progressive disease and/or increasing FGF23 levels. This
strategy seems justified in view of the benign course of TIO.
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